Dysregulation of inflammasome activation in glioma

Sim, JeongMin; Park, JeongMan; Moon, Jong-Seok; Lim, Jaejoon

doi:10.1186/s12964-023-01255-5

Cited by 6 publications

(2 citation statements)

References 241 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dysregulation of the inflammasome leads to aberrant inflammatory responses that enhance tumor progression and invasion of gliomas 105 . CircXRCC5 was highly expressed in glioma and positively related to poor prognosis.…”

Section: Inhibition Of Pyroptosismentioning

confidence: 99%

Pyroptosis in glioma: Current management and future application

Guo,

Su,

Wei

et al. 2023

Immunological Reviews

View full text Add to dashboard Cite

SummaryGlioma, the predominant form of central nervous system (CNS) malignancies, presents a significant challenge due to its high prevalence and low 5‐year survival rate. The efficacy of current treatment methods is limited by the presence of the blood–brain barrier, the immunosuppressive microenvironment, and other factors. Immunotherapy has emerged as a promising approach, as it can overcome the blood–brain barrier. A tumor's immune privilege, which is induced by an immunosuppressive environment, constricts immunotherapy's clinical impact in glioma. Pyroptosis, a programmed cell death mechanism facilitated by gasdermins, plays a significant role in the management of glioma. Its ability to initiate and regulate tumor occurrence, progression, and metastasis is well‐established. However, it is crucial to note that uncontrolled or excessive cell death can result in tissue damage, acute inflammation, and cytokine release syndrome, thereby potentially promoting tumor advancement or recurrence. This paper aims to elucidate the molecular pathways involved in pyroptosis and subsequently discuss its induction in cancer therapy. In addition, the current treatment methods of glioma and the use of pyroptosis in these treatments are introduced. It is hoped to provide more ideas for the treatment of glioma.

show abstract

Section: Inhibition Of Pyroptosismentioning

confidence: 99%

Pyroptosis in glioma: Current management and future application

Guo,

Su,

Wei

et al. 2023

Immunological Reviews

View full text Add to dashboard Cite

show abstract

“…Inflammasomes are intracellular multimeric protein complexes that are guardians of cellular integrity and control the integrity of various crucial cellular functions [ 6 ]. They form large multiprotein signaling platforms to cleave and activate caspase-1 (in the canonical pathway), which is a major inflammatory pathway.…”

Section: Introductionmentioning

confidence: 99%

The interaction of inflammasomes and gut microbiota: novel therapeutic insights

Manshouri,

Seif,

Kamali

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

Inflammasomes are complex platforms for the cleavage and release of inactivated IL-1β and IL-18 cytokines that trigger inflammatory responses against damage-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs). Gut microbiota plays a pivotal role in maintaining gut homeostasis. Inflammasome activation needs to be tightly regulated to limit aberrant activation and bystander damage to the host cells. Several types of inflammasomes, including Node-like receptor protein family (e.g., NLRP1, NLRP3, NLRP6, NLRP12, NLRC4), PYHIN family, and pyrin inflammasomes, interact with gut microbiota to maintain gut homeostasis. This review discusses the current understanding of how inflammasomes and microbiota interact, and how this interaction impacts human health. Additionally, we introduce novel biologics and antagonists, such as inhibitors of IL-1β and inflammasomes, as therapeutic strategies for treating gastrointestinal disorders when inflammasomes are dysregulated or the composition of gut microbiota changes.

show abstract